Unicycive Therapeutics Inc (UNCY) - Total Assets
Based on the latest financial reports, Unicycive Therapeutics Inc (UNCY) holds total assets worth $50.61 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See shareholders equity of Unicycive Therapeutics Inc for net asset value and shareholders' equity analysis.
Unicycive Therapeutics Inc - Total Assets Trend (2018–2024)
This chart illustrates how Unicycive Therapeutics Inc's total assets have evolved over time, based on quarterly financial data.
Unicycive Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Unicycive Therapeutics Inc's total assets of $50.61 Million consist of 97.7% current assets and 2.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 82.6% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2024)
This chart illustrates how Unicycive Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of Unicycive Therapeutics Inc.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Unicycive Therapeutics Inc's current assets represent 97.7% of total assets in 2024, a decrease from 100.0% in 2018.
- Cash Position: Cash and equivalents constituted 82.6% of total assets in 2024, down from 86.2% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Unicycive Therapeutics Inc Competitors by Total Assets
Key competitors of Unicycive Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Unicycive Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.83 | 3.61 | 0.07 |
| Quick Ratio | 3.83 | 3.61 | 0.07 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $37.16 Million | $27.28 Million | $-2.67 Million |
Unicycive Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Unicycive Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.56 |
| Latest Market Cap to Assets Ratio | 4.21 |
| Asset Growth Rate (YoY) | 123.2% |
| Total Assets | $31.67 Million |
| Market Capitalization | $133.25 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Unicycive Therapeutics Inc's assets at a significant premium (4.21x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Unicycive Therapeutics Inc's assets grew by 123.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Unicycive Therapeutics Inc (2018–2024)
The table below shows the annual total assets of Unicycive Therapeutics Inc from 2018 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $31.67 Million | +123.16% |
| 2023-12-31 | $14.19 Million | +403.58% |
| 2022-12-31 | $2.82 Million | -84.97% |
| 2021-12-31 | $18.74 Million | +9088.24% |
| 2020-12-31 | $204.00K | +973.68% |
| 2019-12-31 | $19.00K | -34.48% |
| 2018-12-31 | $29.00K | -- |
About Unicycive Therapeutics Inc
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies to address unmet medical needs in the United States. Its drug candidates include UNI 494, a pro-drug of Nicorandil that is being developed as a treatment for acute kidney injury; and Renazorb RZB 012 for the treatment of hyperphosphatemia in patients with chronic kidney disease… Read more